Our results now indicate that, in the setting of a pre-existing inflammatory condition, leptin therapy fuels inflammation and increases disease activity in autoimmunity via the induction of TNFα-producing cells and by metabolically priming immune cells towards a pro-inflammatory phenotype. The gene discussed is TNF; the disease is Autoimmunity.